SG11201811280QA - Improved pharmacokinetic assays for immunoglobulin single variable domains - Google Patents
Improved pharmacokinetic assays for immunoglobulin single variable domainsInfo
- Publication number
- SG11201811280QA SG11201811280QA SG11201811280QA SG11201811280QA SG11201811280QA SG 11201811280Q A SG11201811280Q A SG 11201811280QA SG 11201811280Q A SG11201811280Q A SG 11201811280QA SG 11201811280Q A SG11201811280Q A SG 11201811280QA SG 11201811280Q A SG11201811280Q A SG 11201811280QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- variable domains
- single variable
- immunoglobulin single
- pct
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 238000002732 pharmacokinetic assay Methods 0.000 title abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662353784P | 2016-06-23 | 2016-06-23 | |
PCT/EP2017/065219 WO2017220645A1 (fr) | 2016-06-23 | 2017-06-21 | Dosages pharmacocinétiques améliorés pour domaines variables uniques d'immunoglobulines |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811280QA true SG11201811280QA (en) | 2019-01-30 |
Family
ID=59313197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811280QA SG11201811280QA (en) | 2016-06-23 | 2017-06-21 | Improved pharmacokinetic assays for immunoglobulin single variable domains |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190195866A1 (fr) |
EP (2) | EP3475699B1 (fr) |
JP (1) | JP7150618B2 (fr) |
KR (1) | KR102374912B1 (fr) |
CN (1) | CN109313183B (fr) |
AU (1) | AU2017281421A1 (fr) |
BR (1) | BR112018076569A2 (fr) |
CA (1) | CA3029133C (fr) |
ES (1) | ES2926014T3 (fr) |
IL (1) | IL263704B1 (fr) |
MX (1) | MX2018016413A (fr) |
PL (1) | PL3475699T3 (fr) |
PT (1) | PT3475699T (fr) |
RU (1) | RU2765809C2 (fr) |
SG (1) | SG11201811280QA (fr) |
WO (1) | WO2017220645A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019099999A1 (fr) * | 2017-11-20 | 2019-05-23 | Vector Laboratories, Inc. | Procédés et systèmes pour la détection d'immunoessai d'une espèce sur une espèce |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
CA2505325C (fr) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Anticorps a domaine unique stabilises |
WO2004062551A2 (fr) | 2003-01-10 | 2004-07-29 | Ablynx N.V. | Polypeptides therapeutiques, leurs homologues, leurs fragments, que l'on utilise dans la modulation de l'agregation plaquettaire |
BRPI0518622A2 (pt) | 2004-12-02 | 2008-12-02 | Domantis Ltd | usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento |
HUE045710T2 (hu) | 2005-05-18 | 2020-01-28 | Ablynx Nv | Javított, alfa tumor nekrózis faktor elleni nanobodies |
BRPI0609797B8 (pt) | 2005-05-20 | 2021-05-25 | Ablynx Nv | nanocorpos melhorados para o tratamento de desordens mediadas por agregação |
CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
CN101466734A (zh) | 2005-12-01 | 2009-06-24 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的竞争性域抗体形式 |
WO2007063308A2 (fr) | 2005-12-01 | 2007-06-07 | Domantis Limited | Formats d'anticorps a domaine non competitif qui lient le recepteur type 1 d'interleukine 1 |
FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
AU2007237501A1 (en) * | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
WO2008020079A1 (fr) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6 |
MX2009012044A (es) * | 2007-05-07 | 2009-11-18 | Wyeth Corp | Eliminacion de interferencia en inmunoensayos causada por anticuerpos anti-carbohidrato. |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
WO2009095489A2 (fr) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6 |
DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
KR20110020825A (ko) | 2008-05-16 | 2011-03-03 | 아블린쓰 엔.브이. | Cxcr4 및 다른 gpcr에 대해 유도된 아미노산 서열 및 이를 포함하는 화합물 |
WO2010130832A2 (fr) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Séquences d'acides aminés dirigées contre dickkopf-1 et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies associées à la déperdition osseuse et/ou à l'ostéolyse |
CN102459332B (zh) | 2009-06-05 | 2015-08-19 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
WO2011073180A1 (fr) * | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique |
WO2012042026A1 (fr) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Matières biologiques associées à c-met |
WO2012175400A1 (fr) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Protéines se liant à la sérumalbumine |
US20150158948A9 (en) * | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
RU2700630C2 (ru) | 2011-06-23 | 2019-09-18 | Аблинкс Нв | Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов |
FR2979099B1 (fr) | 2011-08-16 | 2014-02-28 | Oreal | Tete de distribution de produit pour un recipient et dispositif de distribution associe |
MX2014001883A (es) * | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
CN103293299B (zh) * | 2012-02-24 | 2016-06-08 | 珀金埃尔默医学诊断产品(上海)有限公司 | 拓宽双抗体夹心免疫检测浓度范围的方法及其试剂盒 |
CN103884842A (zh) * | 2014-04-03 | 2014-06-25 | 王少雄 | 针对elisa检测用特异性抗体对的筛选方法 |
RS63085B1 (sr) | 2014-05-16 | 2022-04-29 | Ablynx Nv | Varijabilni domeni imunoglobulina |
CN104597232B (zh) * | 2014-12-03 | 2017-05-03 | 中国科学院理化技术研究所 | 一种可扩展检测范围的捕获抗体竞争夹心免疫检测方法及生物传感器 |
-
2017
- 2017-06-21 RU RU2019101609A patent/RU2765809C2/ru active
- 2017-06-21 IL IL263704A patent/IL263704B1/en unknown
- 2017-06-21 WO PCT/EP2017/065219 patent/WO2017220645A1/fr unknown
- 2017-06-21 JP JP2018567281A patent/JP7150618B2/ja active Active
- 2017-06-21 CA CA3029133A patent/CA3029133C/fr active Active
- 2017-06-21 PL PL17737492.3T patent/PL3475699T3/pl unknown
- 2017-06-21 CN CN201780038584.3A patent/CN109313183B/zh active Active
- 2017-06-21 PT PT177374923T patent/PT3475699T/pt unknown
- 2017-06-21 EP EP17737492.3A patent/EP3475699B1/fr active Active
- 2017-06-21 SG SG11201811280QA patent/SG11201811280QA/en unknown
- 2017-06-21 EP EP22178896.1A patent/EP4119944A1/fr not_active Withdrawn
- 2017-06-21 AU AU2017281421A patent/AU2017281421A1/en active Pending
- 2017-06-21 ES ES17737492T patent/ES2926014T3/es active Active
- 2017-06-21 MX MX2018016413A patent/MX2018016413A/es unknown
- 2017-06-21 US US16/310,291 patent/US20190195866A1/en active Pending
- 2017-06-21 BR BR112018076569A patent/BR112018076569A2/pt unknown
- 2017-06-21 KR KR1020197002311A patent/KR102374912B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2019101609A3 (fr) | 2020-07-23 |
AU2017281421A1 (en) | 2019-01-24 |
ES2926014T3 (es) | 2022-10-21 |
IL263704B1 (en) | 2024-05-01 |
BR112018076569A2 (pt) | 2019-04-02 |
PT3475699T (pt) | 2022-08-30 |
RU2765809C2 (ru) | 2022-02-03 |
CN109313183A (zh) | 2019-02-05 |
IL263704A (en) | 2019-01-31 |
CN109313183B (zh) | 2022-10-21 |
US20190195866A1 (en) | 2019-06-27 |
WO2017220645A1 (fr) | 2017-12-28 |
KR20190020806A (ko) | 2019-03-04 |
JP2019522796A (ja) | 2019-08-15 |
CA3029133A1 (fr) | 2017-12-28 |
EP4119944A1 (fr) | 2023-01-18 |
PL3475699T3 (pl) | 2022-09-26 |
RU2019101609A (ru) | 2020-07-23 |
CA3029133C (fr) | 2024-04-30 |
EP3475699B1 (fr) | 2022-07-06 |
KR102374912B1 (ko) | 2022-03-16 |
JP7150618B2 (ja) | 2022-10-11 |
MX2018016413A (es) | 2019-05-09 |
EP3475699A1 (fr) | 2019-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201809913PA (en) | Methods for detecting target nucleic acids in a sample | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201805906WA (en) | Diagnostic and prognostic methods for cardiovascular diseases and events | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201903693QA (en) | Polypeptide variants and uses thereof | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11201808994YA (en) | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11201901468SA (en) | Antibodies with reduced binding to process impurities | |
SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
SG11201809473QA (en) | Humanized anti-basigin antibodies and the use thereof | |
SG11201901172QA (en) | A method for manufacturing a fuel component | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201808882QA (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer |